Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 13/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1105869 | 0.92 | CASR (0.47) | CASRDRD2SLC6A4DRD1DRD4 | |
| SCHEMBL1105930 | 0.90 | CCR5 (0.47) | CASRDRD4 | |
| SCHEMBL1106042 | 0.89 | CASR (0.45) | CASRDRD2SLC6A4DRD4DRD3 | |
| SCHEMBL1105901 | 0.89 | CASR (0.45) | CASR | |
| SCHEMBL1106044 | 0.87 | ACHE (0.46) | CASR | |
| SCHEMBL1105911 | 0.87 | ACKR3 (0.46) | CASRDRD4 | |
| SCHEMBL1106040 | 0.86 | CASR (0.47) | CASR | |
| SCHEMBL1106065 | 0.85 | CASR (0.43) | CASR | |
| SCHEMBL1105953 | 0.85 | CASR (0.42) | CASRDRD2DRD4 | |
| SCHEMBL1148131 | 0.84 | CASR (0.44) | CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | CASR 1/4885DRD2 451/4885SLC6A4 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.